What follows is how each of those tests works, where they differ, what can distort a result, and the questions worth asking the person who orders your bloodwork.
It measures the effort behind your blood sugar rather than the blood sugar itself. After you eat, beta cells in the pancreas release insulin, which moves glucose into muscle and fat cells and signals the liver to slow its own glucose output. When those tissues respond less readily to the same signal, the pancreas compensates by releasing more insulin, and blood glucose can sit comfortably inside the usual range while insulin output quietly climbs. So any test aimed at insulin resistance has to look at insulin, or at a stand-in for insulin, alongside glucose.
Fasting Insulin is the most direct routine version of that question, because it captures how much insulin your body needs overnight simply to hold fasting glucose steady. The available methods sit on a spectrum, from laboratory infusion procedures that measure insulin action directly, through dynamic tests using a glucose load, down to simple indices calculated from one fasting blood draw 1.
One point is easy to miss. Insulin secretion and insulin sensitivity are read as a pair, since the same insulin number means something different depending on how much insulin the pancreas is still able to produce 2. A modest insulin value in someone with rising glucose is not the same observation as a modest insulin value in someone whose glucose is stable. This is why a single number, taken alone and without context, is a weak basis for any conclusion, and why interpretation belongs with a clinician who can see the whole panel and the person in front of them.
Because compensation works, right up until it does not. The pancreas can increase insulin output for a long stretch to keep fasting and post-meal glucose inside familiar limits, which means glucose can be the last marker to move. Reading secretion against sensitivity is the standard way to describe that compensation, since beta cell output and tissue responsiveness shift together rather than independently 2.
Practically, this is the whole argument for measuring insulin rather than waiting on glucose. If you only ever check fasting glucose and HbA1c, you are watching the end of the process. Adding an insulin measure, or a surrogate built from routine lipids, gives you an earlier and more sensitive view of the same metabolic question. Surrogate indices exist precisely because clinicians and researchers wanted a usable estimate of insulin resistance outside specialist laboratory settings 3.
There is a behavioural payoff too. People who see an insulin number tend to understand why their appetite, energy dips and post-meal slumps behave the way they do, because the number describes something they feel rather than an abstract future risk. That said, none of this is a diagnosis. A raised fasting insulin or a high surrogate index is an observation. It may reflect body composition, activity patterns, sleep, illness or other factors, and it is worth discussing with a clinician rather than acting on alone.
Five approaches cover almost everything you will be offered, and they differ mainly in how much they measure directly versus how much they estimate. The table below sets out what each one looks at and what it costs you in time and complexity.
| Test | What it looks at | What it needs | Practical notes |
|---|---|---|---|
| Hyperinsulinaemic euglycaemic clamp | Whole-body insulin action, measured directly | Controlled insulin and glucose infusions with repeated sampling over several hours | The reference method, essentially a specialist laboratory procedure rather than a routine order |
| Glucose tolerance test with insulin sampling | The dynamic glucose and insulin response to a standard glucose drink | A fasting start, a glucose load and timed draws across a few hours | Shows the shape of the response, not just the fasting state |
| HOMA-IR | Fasting insulin and fasting glucose combined into a single index | One fasting blood draw that includes an insulin assay | Easy to repeat and track over time; describes the fasting state, which the liver dominates |
| TyG index | Fasting triglycerides and fasting glucose combined into a single index | One fasting blood draw, no insulin assay required | Useful where insulin testing is unavailable or expensive |
| HbA1c | Average glycation of hemoglobin across the red cell lifespan | A blood draw, fasting not required | A glucose history marker, not an insulin measure |
Most people asking about an insulin resistance test end up with some combination of rows three, four and five, because those come from ordinary bloodwork. The first two rows explain why the others are described as estimates rather than measurements.
HOMA-IR is a calculation, not a separate blood test, and it comes from fasting insulin and fasting glucose drawn in the same sample. The original formula multiplies the two fasting values and divides by a fixed constant, with the constant depending on the units your laboratory reports glucose in. Nothing extra is drawn, which is why many labs and health platforms report the index automatically once both inputs are present.
What it captures is the fasting state, which is weighted heavily toward how the liver responds to insulin overnight. That is genuinely useful, and it is also a limitation, because it says less about how muscle handles glucose after a meal. Research suggests that fasting surrogate indices correlate with clamp-derived insulin sensitivity well enough to be informative across groups, while agreement in any single individual is considerably looser 4.
The second limitation is the threshold question. Studies suggest that cut-off values for HOMA-IR differ across populations and settings, so a single universal threshold does not transfer cleanly from one group to another 5. In day to day use, that makes the trend in your own repeated results more informative than a one-off comparison against a borderline number someone quoted online.
The sensible way to use HOMA-IR is as a tracking tool. Same laboratory, same assay, same fasting conditions, measured a few times across a year, tells you far more than one isolated value interpreted in isolation.
The TyG index estimates insulin resistance from fasting triglycerides and fasting glucose, with no insulin assay needed at all. Both inputs appear on a standard fasting lipid and metabolic panel, which is the entire appeal. The triglyceride glucose index is associated with insulin resistance measured by reference methods, which is why it is used as a surrogate marker when direct insulin testing is impractical 6.
It earns its place in three situations. Where insulin assays are not offered or not affordable. Where you already have years of lipid panels sitting in a records system and want a retrospective view. And where you want a second, independent angle on the same question rather than relying on one index alone.
Variants exist that fold in body size. Research suggests that combining the TyG index with measures such as body mass index or waist circumference can improve how closely it tracks insulin resistance compared with the plain index 7. The same threshold caution applies here as with HOMA-IR, since cut-offs for both indices vary between populations 5.
The obvious catch is that triglycerides are influenced by more than insulin signalling. Alcohol intake, a very recent meal, acute illness and genetic lipid patterns all move them. A TyG index calculated from a non-fasting sample is not worth much, and an unexpectedly high result is a reason to look at the lipid panel as a whole rather than to assume one explanation.
Fasting insulin is the single measurement most insulin resistance calculations are built on, drawn after an overnight fast. FitScript's optimal range for fasting insulin is 2 to 5 µU/mL. Compare your result with the range printed on your lab report. Optimal ranges are optimization targets rather than diagnostic cut-offs, and typical reference ranges vary by lab, age and sex.
The full detail on what this marker is, how it is run and how to read a result sits on its own page, so see Fasting Insulin for that. For this guide the point is narrower. One fasting insulin value is a single data point, it is most useful when paired with fasting glucose from the same draw, and a clinician reads it alongside the rest of your bloodwork rather than on its own.
HbA1c adds history, and it misses insulin entirely. It reflects how much glucose has attached to hemoglobin across the lifespan of your red blood cells, so it summarises average glucose exposure over a period of months rather than a single morning. That makes it a steady, repeatable marker that does not care whether you fasted or slept badly the night before.
What it cannot do is tell you how hard your pancreas is working to produce that average. Two people with an identical HbA1c can have very different insulin levels, and the one running higher insulin is doing more work for the same result. This is the central reason a normal HbA1c does not settle the question on its own, and why surrogate insulin indices are used alongside glucose markers rather than instead of them.
HbA1c also has its own interference pattern. Anything that changes red cell turnover, including several inherited hemoglobin variants and conditions affecting red cell lifespan, shifts the result independently of glucose. Laboratories flag many of these, but not all, so a surprising HbA1c that does not match your glucose readings is worth raising with a clinician rather than averaging into your conclusions.
Used well, HbA1c is the long exposure photograph, fasting glucose is the snapshot, and an insulin measure or surrogate index is the light meter telling you how much effort produced the picture.
Because it measures insulin action directly instead of inferring it. In a hyperinsulinaemic euglycaemic clamp, insulin is infused at a steady rate while glucose is infused at whatever rate is required to hold blood glucose constant. The amount of glucose needed to maintain that steady state is the readout, since a person whose tissues respond strongly to insulin requires more glucose to stay level than someone whose tissues respond weakly. The clamp and related infusion procedures remain the reference techniques against which simpler estimates are compared 8.
The trade-off is obvious. It takes hours, requires two lines and frequent sampling, needs trained staff and is expensive, which keeps it inside research and specialist settings rather than routine care 9. You are very unlikely to be offered one, and you do not need one to make useful decisions.
Its practical relevance is as the yardstick. Every index discussed on this page is validated by how well it agrees with clamp results, and knowing the size of that gap keeps expectations honest. Research suggests the agreement between simple surrogate measures and clamp-derived sensitivity is moderate rather than tight, which is the main reason a borderline HOMA-IR should not be treated as a verdict 4.
It adds the dimension that fasting tests cannot give you, which is how your body behaves under load. A standard glucose drink is given after an overnight fast and blood is drawn at set intervals, so glucose and, if requested, insulin are tracked as they rise and fall. Dynamic tests of this kind describe the response over time rather than a single resting point.
The extra information is genuinely different. Some people have unremarkable fasting values but a long, high insulin response after a glucose load, and that pattern is invisible on a fasting panel. Indices derived from timed glucose and insulin values, such as the Matsuda index, were developed to summarise that whole-body response from the curve 9.
The costs are time and tolerance. The test occupies several hours, the glucose drink makes some people feel unwell, and repeated draws are less convenient than one morning sample. Insulin levels are not always included by default either, so if the insulin curve is the reason for ordering the test, that has to be specified at the point of ordering.
For most people asking the question for the first time, a fasting panel is the reasonable starting point and a dynamic test is a considered second step that a clinician recommends based on what the first round showed.
Ask for fasting insulin and fasting glucose on the same blood draw, plus a fasting lipid panel and HbA1c. That single request covers HOMA-IR, the TyG index and the glucose history marker in one visit, which is why it is the most efficient opening move. If you want the indices calculated rather than raw numbers, say so, since not every laboratory reports them automatically.
A few preparation points make the result worth having.
If you are testing because of a specific experience, such as persistent hunger or heavy post-meal fatigue, say that out loud when the tests are ordered. The reason for testing shapes which extras are worth adding and how the results get read.
More things than most people expect, which is why one unexpected value should prompt a repeat rather than a conclusion. The most common problem is simple. The sample was not truly fasting, and even a small amount of food or a sweetened drink raises insulin sharply.
Assay differences are the second issue. Insulin is measured by immunoassays that are not fully standardised across laboratories, so the same sample can return different numbers in different places, and index thresholds inherit that variability. Standardisation and threshold variability are both recognised obstacles to using HOMA-IR and the TyG index as fixed diagnostic criteria 5.
Biology contributes as well. Fasting insulin varies day to day within the same person, acute illness and poor sleep shift it, intense exercise in the preceding day can move glucose handling, and sample handling problems such as hemolysis can affect reported values. Some medicines also influence glucose and lipid markers; ask your prescriber rather than drawing conclusions yourself.
Finally, there is interpretation drift. A surrogate index is an estimate built from two numbers, and treating it as though it measured insulin action directly overstates what it can do. The measured and estimated approaches answer related but not identical questions, and that distinction is part of how these tools are described in clinical and research use 3.
The ones that explain context rather than repeat the same signal. Insulin resistance rarely shows up as a lone abnormality, so a panel built around it is far more informative than any index on its own.
FitScript tests 150+ biomarkers per year and Atlas, FitScript's AI health advisor, interprets them together rather than one at a time, with any treatment decision belonging to a licensed provider after reviewing the member. The general principle holds regardless of where you test. A metabolic marker read beside liver, lipid, thyroid and body composition data tells a far more coherent story than the same marker read alone.
A higher fasting insulin, HOMA-IR or TyG index suggests that more insulin is being produced to achieve the same glucose control, and that observation has several possible explanations rather than one. Body composition, particularly visceral and liver fat, physical activity levels, sleep quality and quantity, recent illness, overall dietary pattern and some medicines can all contribute. None of these can be separated from one another by a blood test, which is why the result opens a conversation rather than closing it.
A lower value generally points the other way, toward tissues responding readily to insulin. The one pattern worth noticing is a low insulin level sitting beside a rising glucose level, because that combination is telling a different story from low insulin with stable glucose. Interpreting insulin alongside glucose rather than in isolation is the standard approach for exactly this reason.
So the honest reading of any result follows three steps. What the value shows, which is a number measured under stated conditions. What it may reflect, which is a short list of plausible contributors. And what is worth discussing with a clinician, which is where a result becomes something you can act on. A suboptimal index is not a diagnosis and does not tell you what, if anything, should change.
Whenever the numbers are clearly outside the standard laboratory range, when they have moved substantially since your last test, or when they sit beside symptoms. Persistent thirst, unexplained weight change, recurring blurred vision, marked fatigue or frequent urination alongside a raised glucose reading are all reasons to contact a clinician promptly rather than waiting for a routine review.
A result that is only slightly outside a typical range, with no symptoms, is usually a prompt for a repeat test under better controlled conditions and a proper conversation about context. Never ignore an abnormal result, and never assume one borderline index means the same thing it meant for someone else, since thresholds for these indices vary between populations.
What happens next is a clinical decision. Any treatment decisions belong to a licensed provider who has reviewed your full history, your examination and your complete panel, and who can weigh the options that are actually appropriate for you. This article is educational and is not medical advice. Discuss your own results and any treatment with a clinician or licensed provider before acting on them.
If persistent appetite is what sent you looking in the first place, the wider list of always hungry causes is a useful companion read, and the same goes for the pattern behind post-meal crashes covered in blood sugar spikes causes. For the question underneath most of this, whether is insulin resistance and diabetes the same, that explainer sets out where the two overlap and where they do not.
The usual starting point is fasting insulin and fasting glucose drawn from the same sample, which together give the HOMA-IR index. A fasting lipid panel allows the TyG index to be calculated from triglycerides and glucose, and HbA1c adds a longer view of glucose exposure. Which combination you are offered depends on what your clinician is trying to answer.
Yes for the insulin, glucose and triglyceride measurements, because eating raises all three and makes the indices meaningless. Follow the fasting instruction given by the laboratory or the clinician who ordered the test rather than a general figure. HbA1c is the exception, since it does not require fasting.
HOMA-IR is a calculation, not an extra blood test. It combines your fasting insulin and fasting glucose into one number that estimates how much insulin your body needs overnight to hold glucose steady. A higher number suggests more insulin is being produced for the same result, and a clinician interprets it alongside the rest of your panel.
Neither is simply better; they answer the same question from different angles. HOMA-IR uses an insulin measurement directly, while the TyG index is built from triglycerides and glucose and needs no insulin assay, which makes it practical where insulin testing is unavailable or costly. Many clinicians find it useful to look at both.
No. HbA1c reflects average glucose exposure over months and says nothing about how much insulin was required to keep that average where it is. Two people with the same HbA1c can have very different insulin levels, which is why an insulin measure or surrogate index is added rather than relied on alone.
At-home collection kits can supply fasting insulin, glucose and lipid values, and the indices are then calculated from those numbers. Sample timing and handling matter a great deal, so follow the kit instructions precisely and collect after a genuine overnight fast. The result still needs a clinician to interpret it in context.
That depends on why you tested, what the first result showed and what has changed since. Repeat testing is most informative when it uses the same laboratory, the same fasting conditions and a similar time of morning, so the comparison is fair. The clinician who ordered the test decides on timing.
Do not ignore it, and do not treat one value as a diagnosis. Take the result to a clinician, who can check whether the sample conditions were right, consider a repeat test and look at the rest of your bloodwork before deciding anything. If you also have symptoms such as marked thirst, unexplained weight change or frequent urination, raise it promptly.